Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q1 FY26 results · Apr–Jun 2025
Cohance Lifesciences reported revenue from operations of ₹549.31 crore (up 138.1% from Q1 FY25) and net profit of ₹46.40 crore (down 23.6% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 549.31 | 230.69 | +138.1% | 402.02 | +36.6% |
| Other income | 14.17 | 18.16 | −21.9% | 10.57 | +34.1% |
| Total income | 563.48 | 248.85 | +126.4% | 412.59 | +36.6% |
| Profit before tax | 62.76 | 83.08 | −24.5% | 51.60 | +21.6% |
| Net profit for the period | 46.40 | 60.76 | −23.6% | 38.73 | +19.8% |
| Attributable to shareholders of the company | 48.88 | — | — | 42.01 | +16.4% |
| EPS, basic (₹) | 1.28 | 2.39 | not comparable | 1.65 | not comparable |
| Net margin (%) | 8.4 | 26.3 | 9.6 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 483.58 | 222.09 | +117.7% | 330.17 | +46.5% |
| Other income | 13.10 | 17.95 | −27.0% | 6.63 | +97.6% |
| Total income | 496.68 | 240.04 | +106.9% | 336.80 | +47.5% |
| Profit before tax | 71.04 | 87.39 | −18.7% | 56.32 | +26.1% |
| Net profit for the period | 52.57 | 65.08 | −19.2% | 44.34 | +18.6% |
| EPS, basic (₹) | 1.38 | 2.56 | not comparable | 1.74 | not comparable |
| Net margin (%) | 10.9 | 29.3 | 13.4 |
Consolidated
- Filed with BSE
- 09 Sep 2025, 19:11 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Sep 2025, 19:11 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE